In late 2015, positive data led to FDA approval for three additional spinal surgery indications for the INFUSE bone graft. Through updated research and improved data displaying the BMP product’s safety and efficacy in a greater number of spinal procedures, Medtronic hopes to improve physician usage of the product and restore INFUSE’s place as a leader in the biologics market. In order to move forward, Medtronic has made it a priority to focus on expanding the clinical indications for INFUSE in the US. Use our tool to access competitor pricing strategies across multiple geographies, and various dynamic case studies from the likes of Germany and China, to benchmark yourself against your competitors and future proof your pricing strategies.
To find out, use our Global Brand Pricing tool to achieve optimal pricing for your devices. Michelson, M.D.How do your competitors set prices in different markets? Will reducing your prices win market share from your main competitors? Do you need to position products differently for different markets? The Divergence-LInterbody Fusion Device and the Pivox Oblique Lateral Spine System incorporate the technology of Gary K. The ACS is a carrier to deliver the rhBMP-2 to the implant site and acts as a scaffold for the formation of new bone, and it will resorb, or disappear, over time.
During surgery, it is applied to an absorbable collagen sponge (ACS). The active ingredient in InfuseBone Graft is rhBMP-2-a manufactured version of a protein already present in the body that promotes new bone growth. Infuse has been on the market since 2002 and has been used in more than one million patients worldwide. InfuseBone Graft is approved for certain spine, oral-maxillofacial, and orthopedic trauma surgeries. "The expanded approval with these PEEK devices for OLIF25, OLIF51, and ALIF procedures provide important options for surgeons and their patients." "Infuse Bone Graft remains one of the most-extensively studied products in Spine that is commercially available today," said Doug King, senior vice president and president of Medtronic's Spine division, which is part of the Restorative Therapies Group at Medtronic. This condition can cause back and/or leg pain, as well as functional problems, such as tingling or numbness in the legs or buttocks or difficulty walking. InfuseBone Graft is used with certain Medtronic interbody fusion devices to treat lumbar degenerative disc disease. "This latest approval addresses some fairly common degenerative spine surgical correction needs." Richard Hynes, president and spine surgeon at the B.A.C.K. "Different spine patients can have very different surgical needs, so the more options surgeons have to combine a clinically-proven bone grafting technology like Infuse with different procedures and implants, the greater the likelihood of successful outcomes," said Dr. Use in ALIF procedures with Divergence-LInterbody Fusion Device at a single level from L2-S1. Use in OLIF 25 procedures with Pivox Oblique Lateral Spine System at a single level from L2-L5. Use in OLIF 51 procedures with Divergence-L Interbody Fusion Device at a single level from L5-S1. The new approved indications for InfuseBone Graft are: This is the second expanded indication in just over two years. Infuse Bone Graft is now approved for use with additional spine implants made of polyetheretherketone (PEEK) in oblique lateral interbody fusion (OLIF 25 and OLIF 51) and anterior lumbar interbody fusion (ALIF) procedures at a single level. Food and Drug Administration (FDA) approval of Infuse Bone Graft in new spine surgery indications.
0 kommentar(er)
